CNS Pharmaceuticals stock analysis
Want to see CNSP full AI Analyst Report?
CNS Pharmaceuticals (CNSP) Stock Price & Analysis
CNSP Stock Chart & Stats
- Day’s Range
- $2.89 - $3.70
- 52-Week Range
- $1.90 - $10.54
- Previous Close
- $3.62
- Volume
- N/A
- Average Volume (3M)
- 13.01K
- Market Cap
- $4.22M
- Enterprise Value
- $12.70M
- Total Cash (Recent Filing)
- $17.21M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 3.53
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- -0.27
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Minimal debt reduces interest obligations and balance-sheet pressure while preserving flexibility to fund clinical programs. The improved equity and asset base since 2023 also indicates that financing has repaired the capital structure, supporting near-term operational resilience.
Improved Liquidity
The substantial cash increase strengthens the company’s ability to continue planned operations without an immediate funding requirement. Management believes resources can fund operations beyond the next twelve months, extending runway for clinical and strategic execution.
Pipeline Expansion Potential
Advanced discussions around a differentiated therapeutic asset could broaden the pipeline beyond existing programs and create a platform for future clinical development. If completed, such a transaction could improve strategic relevance and provide additional long-term growth avenues.
Bears Say
No Commercial Revenue
Without product revenue, the company has not yet demonstrated commercial demand or an operating business model that can independently fund development. The absence of recurring sales leaves future value dependent on clinical progress, partnerships, financing, or eventual commercialization.
Persistent Cash Burn
Ongoing negative operating and free cash flow means the company consumes cash rather than generating funds internally. Continued development therefore depends on maintaining access to external financing, which can constrain strategic flexibility and increase dilution risk over time.
Potential Share Dilution
Expanding equity-plan authorization gives the company flexibility to compensate employees and management, but it also creates additional potential dilution for existing shareholders. This may reduce each holder’s ownership percentage if the newly authorized shares are issued.
CNS Pharmaceuticals News
CNS Pharmaceuticals ‘actively evaluating’ business devlopment opportunities
The company said, “Since announcing its strategic pivot in March 2026 beyond a singular focus on glioblastoma multiforme, the Company has been leveraging its executive team’s multi-functional experience across high-value
CNSP FAQ
What was CNS Pharmaceuticals’s price range in the past 12 months?
What is CNS Pharmaceuticals’s market cap?
When is CNS Pharmaceuticals’s upcoming earnings report date?
How were CNS Pharmaceuticals’s earnings last quarter?
Is CNS Pharmaceuticals overvalued?
Does CNS Pharmaceuticals pay dividends?
What is CNS Pharmaceuticals’s EPS estimate?
How many shares outstanding does CNS Pharmaceuticals have?
What happened to CNS Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CNS Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
CNS Pharmaceuticals
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rami Levin
- Employees
- 8
- Website
- www.cnspharma.com
- Address
- 2100 West Loop South, Houston, TX, 77027, US
CNS Pharmaceuticals (CNSP) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 1 | 15 |
| Technical Analysis | 5 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |













